Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins.
Fiche publication
Date publication
septembre 2021
Journal
Diabetes & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence, Pr PETIT Jean-Michel, Pr VERGES Bruno
Tous les auteurs :
Vergès B, Hassid J, Rouland A, Bouillet B, Simoneau I, Petit JM, Duvillard L
Lien Pubmed
Résumé
Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.
Mots clés
Diabetes, LDL, Lipids, PCSK9, Statin
Référence
Diabetes Metab. 2021 Sep 19;:101284